The physiological determinants and risk correlations of elevated heart rate

American Journal of Hypertension

Volumn 12, Issue 1 SUPPL. 1, 1999, Pages 3S-8S

  Palatini, Paolo ^a   Julius, Stevo ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cardiovascular risk; Heart rate; Hypertension; Insulin resistance; Sympathetic system; Tachycardia

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

AGING; ATHEROSCLEROSIS; COMORBIDITY; HEMATOCRIT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MONKEY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TACHYCARDIA;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; FOLLOW-UP STUDIES; HEART RATE; HEMATOCRIT; HUMANS; INSULIN; LIPIDS; RISK FACTORS;

EID: 0033020527     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00207-6     Document Type: Article

References (56)

1. Reed D, McGee D, Yano K: Biological and social correlates of blood pressure among Japanese men in Hawaii. Hypertension 1982;4:406-414.
2. Levy RL, White PD, Stroud WD, et al: Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA 1945;129:585-588.
3. Filipovsky J, Ducimetiere P, Safar ME: Prognostic significance of exercise blood pressure and heart rate in middle-aged men. Hypertension 1992;20:333-339.
4. Kannel WB, Sorlie P: Hypertension in Framingham, in Paul O (ed): Epidemiology and Control of Hypertension. Stratton, New York, 1975, pp 553-592.
5. Cirillo M, Laurenzi M, Trevisan M, et al: Hematocrit, blood pressure, and hypertension. The Gubbio Population Study. Hypertension 1992;20:319-326.
6. Palatini P, Julius S: Review article: heart rate and the cardiovascular risk. J Hypertens 1997;15:3-17.
7. Palatini P, Julius S: Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 1997;11(suppl 1);19-27.
8. Stamler J, Berkson DM, Dyer A, et al: Relationship of multiple variables to blood pressure-Findings from four Chicago epidemiologic studies, in Paul O (ed): Epidemiology and Control of Hypertension. Symposia Specialists, Miami, 1975, pp 307-352.
9. Selby JV, Friedman GD, Quesenberry CP, Jr: Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990;131:1017-1027.
10. Garrison RJ, Kannel WB, Stokes J, III: Incidence and precursors of hypertension in young adults. Prev Med 1987;16:235-251.
11. Medalie JH, Kahn HA, Neufeld HN, et al: Five-year myocardial infarction incidence. II. Association of single variables to age and birthplace. J Chronic Dis 1973; 26:329-349.
12. Schroll M, Hagerup LM: Risk factors of myocardial infarction and death in men aged 50 at entry. A tenyear prospective study from the Glostrup population studies. Dan Med Bull 1977;24:252-255.
13. Dyer AR, Persky V, Stamler J, et al: Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980;112:736-749.
14. Gillum RF, Makuc DM, Feldman JJ: Pulse rate, coronary heart disease, and death: The NHANES I epidemiologic follow-up study. Am Heart J 1991;121:172-177.
15. Kannel WB, Wilson P, Blair SN: Epidemiologic assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J 1985;109:876-885.
16. Kannel WB, Kannel C, Paffenbarger RS, Jr, et al: Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J 1987;113:1489-1494.
17. Gillman MW, Kannel WB, Belanger A, et al: Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J 1993;125: 1148-1154.
18. Palatini P, Casiglia E, Pauletto P, et al: Relationship of tachycardia with high blood pressure and metabolic abnormalities. A study with mixture analysis in three populations. Hypertension 1997;30:1267-1273.
19. Schork NJ, Weder AB, Schork MA, et al: Disease entities, mixed multi-normal distributions, and the role of the hyperkinetic state in the pathogenesis of hypertension. Stat Med 1990;9:301-314.
20. Kaplan JR, Manuck SB, Clarkson TB: The influence of heart rate on coronary artery atherosclerosis. J Cardiovasc Pharmacol 1987;10(suppl 2):S100-S102.
21. Kaplan JR, Manuck SB, Adams MR, et al: Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation 1987;76:1364-1372.
22. Beere PA, Glagov S, Zarins CK: Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984;226:180-182.
23. Palatini P: Exercise haemodynamic in the normotensive and the hypertensive subject. Clin Sci 1994;87:275-287
24. Julius S: Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993;21:886-893.
25. Julius S, Li Y, Brant D, et al: Neurogenic pressor episodes fail to cause hypertension, but do induce cardiac hypertrophy. Hypertension 1989;13:424-429.
26. Hartford M, Wikstrand JCM, Wallentin I, et al: Left ventricular mass in middle-aged men. Relationship to blood pressure, sympathetic nervous activity, hormonal and metabolic factors. Clin Exper Hypertens [A] 1983;A5:1429-1451.
27. Marcus R, Krause L, Weder AB, et al: Sex-specific determinants of increased left ventricular mass in the Tecumseh blood pressure study. Circulation 1994;90: 928-936.
28. Palatini P, Maraglino G, Accurso V, et al: Impaired left ventricular filling in hypertensive left ventricular hypertrophy as a marker of the presence of an arrhythmogenic substrate. Br Heart J 1995;73:258-262.
29. Levy D, Garrison RJ, Savage DD, et al: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990;322:1561-1566.
30. Hohlnoser SH, Klingenheben T, van de Loo A, et al: Reflex versus tonic vagal activity as a prognostic parameter in patients with sustained ventricular tachyardia or ventricular fibrillation. Circulation 1994; 89:1068-1073.
31. Lown B, Verrier RL: Neural activity and ventricular fibrillation. N Engl J Med 1976;294:1165.
32. Julius S, Pascual AV, London R: Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 1971;44:413-418.
33. Bohm R, van Baak M, van Hooff M, et al: Salivary flow in borderline hypertension. Klin Wochenschr 1985; 63(suppl 3):154-156.
34. Guzzetti S, Piccaluga E, Casati R, et al: Sympathetic predominance in essential hypertension: a study employing spectral analysis of heart rate variability. J Hypertens 1988;6:711-717.
35. Parati G, Philip SJ, DiRienzo M, Mancia G: Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation. A critical appraisal. Hypertension 1995;25:1276-1286.
36. Palatini P, Visentin PA, Mormino P, et al: Left ventricular performance in the early stages of systemic hypertension. Am J Cardiol 1998;81:418-423.
37. Julius S: Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension. Circ Res 1975;36-37(suppl.I):I-199-I-207.
38. Langer RD, Ganiats TG, Barrett-Connor E: Paradoxical survival of elderly men with high blood pressure. Br Med J 1989;298:1356-1358.
39. Staessen J, Amery A, Birkenhager W, et al: Is high serum cholesterol level associated with longer survival in elderly hypertensives? J Hypertens 1990;8:755-760.
40. Aronow WS, Ahn C, Mercando AD, et al: Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol 1996;78:1175-1176.
41. Palatini P, Casiglia E, Julius S, et al: Heart rate: a risk factor for cardiovascular mortality in elderly men. Arch Int Med (in press).
42. Tsuji H, Venditti FJ, Manders ES, et al: Reduced heart rate variability and mortality risk in an elderly cohort. Circulation 1994;90:878-883.
43. Bassiouny HS, Zarins CK, Kadowaki MH, et al: Hemodynamic stress and experimental aortoiliac atherosclerosis. J Vasc Surg 1994;19:426-434.
44. Kjekshus JK: Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57:43F-49F.
45. Kjekshus JK: Comments on beta-blockers: heart rate reduction, a mechanism of action. Eur Heart J 1985; 6(suppl):29.
46. Hjalmarson A, Herlitz J, Holmberg S, et al: The Goteborg Metoprolol Trial in acute myocardial infarction. Am J Cardiol 1984;53:10D-50D.
47. The International Collaborative Study Group: Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 1984;310:9-15.
48. Taylor SH, Silke B, Ebbutt A, et al: A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med 1982;307:1293-1301.
49. Nul DR, Doval HC, Grancelli HO, et al: Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 1997;29:1199-1205.
50. Packer M, Bristow MR, Cohn JN, for the U.S. Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
51. Farmer JA, Gotto AM Jr: Dyslipidemia and other risk factors for coronary artery disease, in Braunwald E (ed): Heart Disease, Vth Edition. Saunders Company, Philadelphia, 1997, pp 1126-1160.
52. Stadler P, Leonardi L, Riesen W, et al: Cardiovascular effects of verapamil in essential hypertension. Clin Pharmacol Ther 1987;42:85-92.
53. Kailasam MT, Parmer RJ, Cervenka JH, et al: Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995;26:143-149.
54. Luscher TF, Clozel JP, Noll G: Pharmacology of the calcium antagonist mibefradil. J Hypertens 1997; 15(suppl 3):S11-S18.
55. Head GA: Central monoamine systems and new antihypertensive agents. Clin Exp Hypertens 1995;17:141-152.
56. Ernsberger P, Koletsky RJ, Collins LA, et al: Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholitic agent. Cardiovasc Drugs Ther 1996;10:275-282.